<DOC>
	<DOCNO>NCT02415595</DOCNO>
	<brief_summary>The purpose study find least one dose BMS-955176 safe , effective tolerable HIV-1 infect treatment naive adult .</brief_summary>
	<brief_title>Dose-finding Study BMS-955176 Treat HIV-1 Infected Treatment-naive Adults</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Men nonpregnant woman , least 18 year age Antiretroviral treatmentnaïve ; define current previous exposure &gt; 1 week antiretroviral drug Plasma HIV1 RNA ≥ 1000 copies/mL CD4 Tcell count &gt; 200 cells/mm3 Resistance partial resistance study drug determine test Screening Current historical genotypic and/or phenotypic drug resistance test show certain resistance mutation EFV , TDF , FTC , Protease Inhibitors Chronic hepatitis B virus ( HBV ) / hepatitis C virus ( HCV ) Blood test indicate normal liver function Hemoglobin &lt; 8.0 g/dL , platelet &lt; 50,000 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>